Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal dry mannitol for chronic rhinosinusitis
ACTRN12612001008819Phase 3Not yet recruiting
- Sponsor
- Dr Emad Massoud
- Start
- Nov 2012
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of Bronchitol in chronic rhinosinusitis (CRS) (2 arms), sponsored by Dr Emad Massoud. Primary endpoint: Symptom control by SNOT-22. Planned start Nov 2012; status: not yet recruiting.
02
Drugs
Bronchitol
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on ACTRN12612001008819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001008819.